Emerging role of high-mobility group box 1 (HMGB1) in liver diseases

Molecular Medicine

Volumn 19, Issue 1, 2013, Pages 357-366

  Chen, Ruochan ^a,b   Hou, Wen ^a   Zhang, Qiuhong ^a   Kang, Rui ^a   Fan, Xue Gong ^b   Tang, Daolin ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

4 CHLORO N (3 QUINUCLIDINYL)BENZAMIDE; ACETYLCYSTEINE; ADVANCED GLYCATION END PRODUCT RECEPTOR; ALPHA SMOOTH MUSCLE ACTIN; ASCORBIC ACID 2 [3,4 DIHYDRO 2,5,7,8 TETRAMETHYL 2 (4,8,12 TRIMETHYLTRIDECYL) 2H 1 BENZOPYRAN 6 YL HYDROGEN PHOSPHATE] POTASSIUM; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE; CD11B ANTIGEN; CD14 ANTIGEN; CD24 ANTIGEN; CHEMOKINE RECEPTOR CXCR4; CISPLATIN; HIGH MOBILITY GROUP B1 PROTEIN; HISTONE DEACETYLASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; JANUS KINASE; MATRIX METALLOPROTEINASE; MELATONIN; MITOGEN ACTIVATED PROTEIN KINASE; MYELOID DIFFERENTIATION FACTOR 88; N [2 [[N [3 (4 CHLOROPHENYL) 2 PROPENYL] N METHYLAMINO]METHYL]PHENYL] N (2 HYDROXYETHYL) 4 METHOXYBENZENESULFONAMIDE; NEUTRALIZING ANTIBODY; PARACETAMOL; SMALL INTERFERING RNA; SYNDECAN 1; T CELL IMMUNOGLOBULIN MUCIN 3; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 4; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ADSORPTION; AUTOPHAGY; CHEMICAL STRUCTURE; END STAGE LIVER DISEASE; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HEPATITIS DELTA VIRUS; HUMAN; INNATE IMMUNITY; LIVER CELL CARCINOMA; LIVER DISEASE; LIVER FIBROSIS; LIVER INJURY; LIVER REGENERATION; LIVER TRANSPLANTATION; NERVE FIBER GROWTH; NONALCOHOLIC FATTY LIVER; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; PROTEIN SECRETION; PROTEIN STRUCTURE; REPERFUSION INJURY; REVIEW; RNA INTERFERENCE; SIGNAL TRANSDUCTION; SINUSOIDAL CELL INJURY; VIRUS HEPATITIS;

ANIMALS; CELL NUCLEUS; CYTOSOL; DISEASE MODELS, ANIMAL; HMGB1 PROTEIN; HUMANS; LIVER DISEASES; SIGNAL TRANSDUCTION;

EID: 84888325591     PISSN: 10761551     EISSN: None     Source Type: Journal    
DOI: 10.2119/molmed.2013.00099     Document Type: Review

References (121)

1. Goodwin GH, Sanders C, Johns EW. (1973) A new group of chromatin-associated proteins with a high content of acidic and basic amino acids. Eur. J. Biochem. 38:14-9.
2. Calogero S, et al. (1999) The lack of chromosomal protein Hmg1 does not disrupt cell growth but causes lethal hypoglycaemia in newborn mice. Nat. Genet. 22:276-80.
3. Andersson U, Tracey KJ. (2011) HMGB1 is a therapeutic target for sterile inflammation and infection. Annu. Rev. Immunol. 29:139-62.
4. Harris HE, Andersson U, Pisetsky DS. (2012) HMGB1: a multifunctional alarmin driving autoimmune and inflammatory disease. Nat. Rev. Rheumatol. 8:195-202.
5. Kang R, Zhang Q, Zeh HJ 3rd, Lotze MT, Tang D. (2013) HMGB1 in cancer: good, bad, or both? Clin. Cancer Res. 19:4046-57.
6. Weir HM, et al. (1993) Structure of the HMG box motif in the B-domain of HMG1. EMBO J. 12:1311-9.
7. Hardman CH, et al. (1995) Structure of the A-domain of HMG1 and its interaction with DNA as studied by heteronuclear three-and four-dimensional NMR spectroscopy. Biochemistry. 34:16596-607.
8. Read CM, Cary PD, Crane-Robinson C, Driscoll PC, Norman DG. (1993) Solution structure of a DNA-binding domain from HMG1. Nucleic Acids Res. 21:3427-36.
9. Li J, et al. (2003) Structural basis for the proinflammatory cytokine activity of high mobility group box 1. Mol. Med. 9:37-45.
10. Yang H, et al. (2004) Reversing established sepsis with antagonists of endogenous high-mobility group box 1. Proc. Natl. Acad. Sci. U. S. A. 101:296-301.
11. Huttunen HJ, Fages C, Kuja-Panula J, Ridley AJ, Rauvala H. (2002) Receptor for advanced glycation end products-binding COOH-terminal motif of amphoterin inhibits invasive migration and metastasis. Cancer Res. 62:4805-11.
12. Yang HA, et al. (2010) A critical cysteine is required for HMGB1 binding to Toll-like receptor 4 and activation of macrophage cytokine release. Proc. Natl. Acad. Sci. U. S. A. 107:11942-7.
13. Venereau E, et al. (2012) Mutually exclusive redox forms of HMGB1 promote cell recruitment or proinflammatory cytokine release. J. Exp. Med. 209:1519-28.
14. Javaherian K, Liu JF, Wang JC. (1978) Nonhistone proteins HMG1 and HMG2 change the DNA helical structure. Science. 199:1345-6.
15. Wang H, et al. (1999) HMG-1 as a late mediator of endotoxin lethality in mice. Science. 285:248-51.
16. Tang D, et al. (2010) HMGB1 release and redox regulates autophagy and apoptosis in cancer cells. Oncogene. 29:5299-310.
17. Yang H, et al. (2012) Redox modification of cysteine residues regulates the cytokine activity of high mobility group box-1 (HMGB1). Mol. Med. 18:250-9.
18. Hreggvidsdottir HS, et al. (2009) The alarmin HMGB1 acts in synergy with endogenous and exogenous danger signals to promote inflammation. J. Leukoc. Biol. 86:655-62.
19. Wahamaa H, et al. (2011) High mobility group box protein 1 in complex with lipopolysaccharide or IL-1 promotes an increased inflammatory phenotype in synovial fibroblasts. Arthritis Res. Ther. 13:R136.
20. Tang D, et al. (2010) Endogenous HMGB1 regulates autophagy. J. Cell Biol. 190:881-92.
21. Tang D, et al. (2011) High-mobility group box 1 is essential for mitochondrial quality control. Cell Metab. 13:701-11.
22. Bonaldi T, et al. (2003) Monocytic cells hyperacetylate chromatin protein HMGB1 to redirect it towards secretion. EMBO J. 22:5551-60.
23. Youn JH, Shin JS. (2006) Nucleocytoplasmic shuttling of HMGB1 is regulated by phosphorylation that redirects it toward secretion. J. Immunol. 177:7889-97.
24. Gardella S, et al. (2002) The nuclear protein HMGB1 is secreted by monocytes via a nonclassical, vesicle-mediated secretory pathway. EMBO Rep. 3:995-1001.
25. Vande Walle L, Kanneganti TD, Lamkanfi M. (2011) HMGB1 release by inflammasomes. Virulence. 2:162-5.
26. Lu B, et al. (2012) Novel role of PKR in inflammasome activation and HMGB1 release. Nature. 488:670-4.
27. Scaffidi P, Misteli T, Bianchi ME. (2002) Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature. 418:191-5.
28. Kazama H, et al. (2008) Induction of immunological tolerance by apoptotic cells requires caspasedependent oxidation of high-mobility group box-1 protein. Immunity. 29:21-32.
29. Dupont N, et al. (2011) Autophagy-based unconventional secretory pathway for extracellular delivery of IL-1beta. EMBO J. 30:4701-11.
30. Taguchi A, et al. (2000) Blockade of RAGEamphoterin signalling suppresses tumour growth and metastases. Nature. 405:354-60.
31. Palumbo R, et al. (2004) Extracellular HMGB1, a signal of tissue damage, induces mesoangioblast migration and proliferation. J. Cell Biol. 164:441-9.
32. Park JS, et al. (2006) High mobility group box 1 protein interacts with multiple Toll-like receptors. Am. J. Physiol. Cell Physiol. 290:C917-24.
33. Tian J, et al. (2007) Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat. Immunol. 8:487-96.
34. Chen GY, Tang J, Zheng P, Liu Y. (2009) CD24 and Siglec-10 selectively repress tissue damageinduced immune responses. Science. 323:1722-5.
35. Chiba S, et al. (2012) Tumor-infiltrating DCs suppress nucleic acid-mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1. Nat. Immunol. 13:832-42.
36. Schiraldi M, et al. (2012) HMGB1 promotes recruitment of inflammatory cells to damaged tissues by forming a complex with CXCL12 and signaling via CXCR4. J. Exp. Med. 209:551-63.
37. van Golen RF, Reiniers MJ, Olthof PB, van Gulik TM, Heger M. (2013) Sterile inflammation in hepatic ischemia/reperfusion injury: present concepts and potential therapeutics. J. Gastroenterol. Hepatol. 28:394-400.
38. Tsung A, et al. (2005) The nuclear factor HMGB1 mediates hepatic injury after murine liver ischemia-reperfusion. J. Exp. Med. 201:1135-43.
39. Watanabe T, et al. (2005) The role of HMGB-1 on the development of necrosis during hepatic ischemia and hepatic ischemia/reperfusion injury in mice. J. Surg. Res. 124:59-66.
40. Nace GW, et al. (2013) Cellular-specific role of tolllike receptor 4 in hepatic ischemia-reperfusion injury in mice. Hepatology. 58:374-87.
41. Cai C, et al. (2013) CD14 contributes to warm hepatic ischemia-reperfusion injury in mice. Shock. 40:115-21.
42. Bamboat ZM, et al. (2010) Toll-like receptor 9 inhibition confers protection from liver ischemiareperfusion injury. Hepatology. 51:621-32.
43. Zeng S, et al. (2009) Receptor for advanced glycation end product (RAGE)-dependent modulation of early growth response-1 in hepatic ischemia/reperfusion injury. J. Hepatol. 50:929-36.
44. Zhu P, et al. (2011) Gene silencing of NALP3 protects against liver ischemia-reperfusion injury in mice. Hum. Gene Ther. 22:853-64.
45. Evankovich J, et al. (2010) High mobility group box 1 release from hepatocytes during ischemia and reperfusion injury is mediated by decreased histone deacetylase activity. J. Biol. Chem. 285:39888-97.
46. Dhupar R, et al. (2011) Interferon regulatory factor 1 mediates acetylation and release of high mobility group box 1 from hepatocytes during murine liver ischemia-reperfusion injury. Shock. 35:293-301.
47. Cardinal J, et al. (2009) Cisplatin prevents high mobility group box 1 release and is protective in a murine model of hepatic ischemia/reperfusion injury. Hepatology. 50:565-74.
48. Ogiku M, Kono H, Hara M, Tsuchiya M, Fujii H. (2011) Glycyrrhizin prevents liver injury by inhibition of high-mobility group box 1 production by Kupffer cells after ischemia-reperfusion in rats. J. Pharmacol. Exp. Ther. 339:93-8.
49. Li F, et al. (2013) The protective effect of PNU-282987, a selective alpha7 nicotinic acetylcholine receptor agonist, on the hepatic ischemiareperfusion injury is associated with the inhibition of high-mobility group box 1 protein expression and nuclear factor kappaB activation in mice. Shock. 39:197-203.
50. Liu A, et al. (2013) The fibrin-derived peptide Bss15-42 attenuates the liver damage in a rat model of liver ischemia reperfusion injury. Shock. 2013, Feb 20 [Epub ahead of print].
51. Oishi K, et al. (2012) The vitamin E derivative, EPC-K1, suppresses inflammation during hepatic ischemia-reperfusion injury and exerts hepatoprotective effects in rats. J. Surg. Res. 176:164-70.
52. Kang JW, Koh EJ, Lee SM. (2011) Melatonin protects liver against ischemia and reperfusion injury through inhibition of toll-like receptor signaling pathway. J. Pineal Res. 50:403-11.
53. Izuishi K, et al. (2006) Cutting edge: high-mobility group box 1 preconditioning protects against liver ischemia-reperfusion injury. J. Immunol. 176:7154-8.
54. Shibayama Y, Asaka S, Nishijima A. (1991) Mechanism of liver injury following ischemia. Exp. Mol. Pathol. 55:251-60.
55. Abu-Amara M, et al. (2010) Liver ischemia/reperfusion injury: processes in inflammatory networks: a review. Liver Transpl. 16:1016-32.
56. Montalvo-Jave EE, Escalante-Tattersfield T, Ortega-Salgado JA, Pina E, Geller DA. (2008) Factors in the pathophysiology of the liver ischemia-reperfusion injury. J. Surg. Res. 147:153-9.
57. Ilmakunnas M, et al. (2008) High mobility group box 1 protein as a marker of hepatocellular injury in human liver transplantation. Liver Transpl. 14:1517-25.
58. El-Serag HB, Rudolph KL. (2007) Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 132:2557-76.
59. Arzumanyan A, Reis HM, Feitelson MA. (2013) Pathogenic mechanisms in HBV-and HCV-associated hepatocellular carcinoma. Nat. Rev. Cancer. 13:123-35.
60. Albayrak A, et al. (2010) Is HMGB1 a new indirect marker for revealing fibrosis in chronic hepatitis and a new therapeutic target in treatment? Viral Immunol. 23:633-8.
61. Jung JH, et al. (2011) Hepatitis C virus infection is blocked by HMGB1 released from virus-infected cells. J. Virol. 85:9359-368.
62. Liu HB, et al. (2007) [Serum level of HMGB1 in patients with hepatitis B and its clinical significance.]. Zhonghua Gan Zang Bing Za Zhi 15:812-5.
63. Zhou RR, et al. (2011) HMGB1 cytoplasmic translocation in patients with acute liver failure. BMC Gastroenterol. 11:21.
64. Cheng BQ, et al. (2008) Serum high mobility group box chromosomal protein 1 is associated with clinicopathologic features in patients with hepatocellular carcinoma. Dig. Liver Dis. 40:446-52.
65. Wang LW, Chen H, Gong ZJ. (2010) High mobility group box-1 protein inhibits regulatory T cell immune activity in liver failure in patients with chronic hepatitis B. Hepatobiliary Pancreat. Dis. Int. 9:499-507.
66. Day CP, James OF. (1998) Steatohepatitis: a tale of two "hits"? Gastroenterology. 114:842-5.
67. Zuiderweg ER, et al. (2013) Allostery in the hsp70 chaperone proteins. Top. Curr. Chem. 328:99-153.
68. Li L, et al. (2011) Nuclear factor high-mobility group box1 mediating the activation of Toll-like receptor 4 signaling in hepatocytes in the early stage of nonalcoholic fatty liver disease in mice. Hepatology. 54:1620-30.
69. Guo J, Friedman SL. (2007) Hepatic fibrogenesis. Semin. Liver Dis. 27:413-26.
70. Kao YH, et al. (2008) High-mobility group box 1 protein activates hepatic stellate cells in vitro. Transplant. Proc. 40:2704-5.
71. Ge WS, Wu JX, Fan JG, Wang YJ, Chen YW. (2011) Inhibition of high-mobility group box 1 expression by siRNA in rat hepatic stellate cells. World J. Gastroenterol. 17:4090-8.
72. Zhang Z, et al. (2012) High mobility group box 1 activates toll like receptor 4 signaling in hepatic stellate cells. Life Sci. 91:207-12.
73. Wang FP, et al. (2013) High mobility group box-1 promotes the proliferation and migration of hepatic stellate cells via TLR4-dependent signal pathways of PI3K/Akt and JNK. PLoS One. 8:e64373.
74. Kostova N, Zlateva S, Ugrinova I, Pasheva E. (2010) The expression of HMGB1 protein and its receptor RAGE in human malignant tumors. Mol. Cell Biochem. 337:251-8.
75. Liu F, et al. (2012) High expression of high mobility group box 1 (hmgb1) predicts poor prognosis for hepatocellular carcinoma after curative hepatectomy. J. Transl. Med. 10:135.
76. Dong YD, et al. (2013) Expression and clinical significance of HMGB1 in human liver cancer: knockdown inhibits tumor growth and metastasis in vitro and in vivo. Oncol. Rep. 29:87-94.
77. Jiang W, Wang Z, Li X, Fan X, Duan Y. (2012) High-mobility group box 1 is associated with clinicopathologic features in patients with hepatocellular carcinoma. Pathol. Oncol. Res. 18:293-8.
78. Liang X, et al. (2009) Ethyl pyruvate administration inhibits hepatic tumor growth. J. Leukoc. Biol. 86:599-607.
79. Yaser AM, et al. (2012) The role of receptor for advanced glycation end products (RAGE) in the proliferation of hepatocellular carcinoma. Int. J. Mol. Sci. 13:5982-97.
80. Yan W, et al. (2012) High-mobility group box 1 activates caspase-1 and promotes hepatocellular carcinoma invasiveness and metastases. Hepatology. 55:1863-75.
81. Dapito DH, et al. (2012) Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4. Cancer Cell. 21:504-16.
82. Lee WM. (2004) Acetaminophen and the U.S. Acute Liver Failure Study Group: lowering the risks of hepatic failure. Hepatology. 40:6-9.
83. Antoine DJ, et al. (2012) Molecular forms of HMGB1 and keratin-18 as mechanistic biomarkers for mode of cell death and prognosis during clinical acetaminophen hepatotoxicity. J. Hepatol. 56:1070-9.
84. Antoine DJ, et al. (2013) Mechanistic biomarkers provide early and sensitive detection of acetaminophen-induced acute liver injury at first presentation to hospital. Hepatology. 58:777-87.
85. Antoine DJ, Williams DP, Kipar A, Laverty H, Park BK. (2010) Diet restriction inhibits apoptosis and HMGB1 oxidation and promotes inflammatory cell recruitment during acetaminophen hepatotoxicity. Mol. Med. 16:479-90.
86. Wang H, Li W, Goldstein R, Tracey KJ, Sama AE. (2007) HMGB1 as a potential therapeutic target. Novartis Found. Symp. 280:73-85; discussion 85-91, 160-164.
87. Wang XF, Sun R, Wei HM, Tian ZG. (2013) Highmobility group box 1 (HMGB1)-toll-like receptor (TLR)4-interleukin (IL)-23-IL-17A axis in drug-induced damage-associated lethal hepatitis: interaction of gamma delta T cells with macrophages. Hepatology. 57:373-84.
88. Tang D, Billiar TR, Lotze MT. (2012) A Janus tale of two active high mobility group box 1 (HMGB1) redox states. Mol. Med. 18:1360-2.
89. Antoine DJ, et al. (2012) Molecular forms of HMGB1 and keratin-18 as mechanistic biomarkers for mode of cell death and prognosis during clinical acetaminophen hepatotoxicity. J. Hepatol. 56:1070-9.
90. Antoine DJ, et al. (2009) High-mobility group box-1 protein and keratin-18, circulating serum proteins informative of acetaminophen-induced necrosis and apoptosis in vivo. Toxicol. Sci. 112:521-31.
91. Dragomir AC, Laskin JD, Laskin DL. (2011) Macrophage activation by factors released from acetaminophen-injured hepatocytes: potential role of HMGB1. Toxicol. Appl. Pharmacol. 253:170-77.
92. Yang R, et al. (2012) High mobility group B1 impairs hepatocyte regeneration in acetaminophen hepatotoxicity. BMC Gastroenterol. 12:45.
93. Gong QA, et al. (2010) High-mobility group box 1 exacerbates concanavalin A-induced hepatic injury in mice. J. Mol. Med. 88:1289-8.
94. Zhou RR, et al. (2011) HMGB1 cytoplasmic translocation in patients with acute liver failure. BMC Gastroenterol. 11:21-31.
95. Taub R. (2004) Liver regeneration: from myth to mechanism. Nat. Rev. Mol. Cell. Biol. 5:836-47.
96. Wang H, Zhu S, Zhou R, Li W, Sama AE. (2008) Therapeutic potential of HMGB1-targeting agents in sepsis. Expert Rev. Mol. Med. 10:e32.
97. Szabo G, Mandrekar P, Dolganiuc A. (2007) Innate immune response and hepatic inflammation. Semin. Liver Dis. 27:339-50.
98. Berasain C, et al. (2009) Inflammation and liver cancer: new molecular links. Ann. N. Y. Acad. Sci. 1155:206-21.
99. Venereau E, et al. (2012) Mutually exclusive redox forms of HMGB1 promote cell recruitment or proinflammatory cytokine release. J. Exp. Med. 209:1519-28.
100. Yang H, et al. (2010) A critical cysteine is required for HMGB1 binding to Toll-like receptor 4 and activation of macrophage cytokine release. Proc. Natl. Acad. Sci. U. S. A. 107:11942-7.
101. Abeyama K, et al. (2005) The N-terminal domain of thrombomodulin sequesters highmobility group-B1 protein, a novel antiinflammatory mechanism. J. Clin. Invest. 115:1267-74.
102. Kim ID, et al. (2012) Intranasal delivery of HMGB1 siRNA confers target gene knockdown and robust neuroprotection in the postischemic brain. Mol. Ther. 20:829-39.
103. Livesey K, et al. (2012) p53/HMGB1 complexes regulate autophagy and apoptosis. Cancer Res. 72:1996-2005.
104. Yamamoto T, et al. (2010) Hemoperfusion with a high-mobility group box 1 adsorption column can prevent the occurrence of hepatic ischemia-reperfusion injury in rats. Crit. Care Med. 38:879-85.
105. Xie K, et al. (2010) Protective effects of hydrogen gas on murine polymicrobial sepsis via reducing oxidative stress and HMGB1 release. Shock. 34:90-7.
106. Tang D, et al. (2009) Quercetin prevents LPSinduced high-mobility group box 1 release and proinflammatory function. Am. J. Respir. Cell Mol. Biol. 41:651-60.
107. Wang L, et al. (2010) Atorvastatin protects rat brains against permanent focal ischemia and downregulates HMGB1, HMGB1 receptors (RAGE and TLR4), NF-kappaB expression. Neurosci. Lett. 471:152-6.
108. Wang L, et al. (2010) Tanshinone II A downregulates HMGB1, RAGE, TLR4, NF-kappaB expression, ameliorates BBB permeability and endothelial cell function, and protects rat brains against focal ischemia. Brain Res. 1321:143-51.
109. Schierbeck H, Wahamaa H, Andersson U, Harris HE. (2010) Immunomodulatory drugs regulate HMGB1 release from activated human monocytes. Mol. Med. 16:343-51.
110. Yang M, et al. (2013) Chloroquine inhibits HMGB1 inflammatory signaling and protects mice from lethal sepsis. Biochem. Pharmacol. 86:410-8.
111. Ulloa L, et al. (2002) Ethyl pyruvate prevents lethality in mice with established lethal sepsis and systemic inflammation. Proc. Natl. Acad. Sci. U. S. A. 99:12351-6.
112. Mollica L, et al. (2007) Glycyrrhizin binds to high-mobility group box 1 protein and inhibits its cytokine activities. Chem. Biol. 14:431-41.
113. Chen G, et al. (2005) Suppression of HMGB1 release by stearoyl lysophosphatidylcholine: an additional mechanism for its therapeutic effects in experimental sepsis. J. Lipid Res. 46:623-7.
114. Wang H, et al. (2006) The aqueous extract of a popular herbal nutrient supplement, Angelica sinensis, protects mice against lethal endotoxemia and sepsis. J. Nutr. 136:360-5.
115. Li W, et al. (2007) A cardiovascular drug rescues mice from lethal sepsis by selectively attenuating a late-acting proinflammatory mediator, high mobility group box 1. J. Immunol. 178:3856-64.
116. Li W, et al. (2007) A major ingredient of green tea rescues mice from lethal sepsis partly by inhibiting HMGB1. PLoS One. 2:e1153.
117. Li W, et al. (2011) EGCG stimulates autophagy and reduces cytoplasmic HMGB1 levels in endotoxin-stimulated macrophages. Biochem. Pharmacol. 81:1152-63.
118. Zhu S, et al. (2012) It is not just folklore: the aqueous extract of mung bean coat is protective against sepsis. Evid. Based Complement Alternat. Med. 2012:498467.
119. Liliensiek B, et al. (2004) Receptor for advanced glycation end products (RAGE) regulates sepsis but not the adaptive immune response. J. Clin. Invest. 113:1641-50.
120. Hagiwara S, Iwasaka H, Hasegawa A, Koga H, Noguchi T. (2008) Effects of hyperglycemia and insulin therapy on high mobility group box 1 in endotoxin-induced acute lung injury in a rat model. Crit. Care Med. 36:2407-13.
121. Wang H, et al. (2004) Cholinergic agonists inhibit HMGB1 release and improve survival in experimental sepsis. Nat. Med. 10:1216-21.